BioWisdom’s intelligence networks are codified knowledge drawn from diverse information taken from public, third party and in-house sources.
“We have been working with BioWisdom for the past two years and have been impressed by the potential of its latest technology development to enhance our scientific understanding of the cause and effects around drug toxicity” said David Cook, associate director, pathways capability at AstraZeneca. “By understanding the effects previous drugs have exhibited on drug toxicity biomarker profiles, in combination with clinical disorders and other factors, we hope to be better able to guide our own discovery and development activities.”
In the extension to the collaboration, AstraZeneca will further evaluate BioWisdom’s Sofia Platform for the development of intelligence networks elsewhere in the business. Financial details were not disclosed.